Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality.

Autor:	Waters L; Department of Sexual Health & HIV, Central & North West London NHS Trust, London, United Kingdom., de Miguel-Buckley R; Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital, IdiPAZ, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain., Poulin S; Centre intégré de santé et de services sociaux des Laurentides, Clinique I.D., Saint-Jérôme, Québec, Canada., Arribas JR; Infectious Diseases Unit, Internal Medicine Department, La Paz University Hospital, IdiPAZ, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Mar 21; Vol. 76 (6), pp. 1136-1141.
DOI:	10.1093/cid/ciac835
Abstrakt:	In this viewpoint, we briefly review the status of antiretroviral therapy (ART), its unmet needs, and the role that broadly neutralizing antibodies (bNAbs) might have in the near future for the treatment of human immunodeficiency virus (HIV). We summarize advances in the development of bNAbs as antiretroviral therapy, the results of main clinical trials of bNAbs for HIV treatment and prevention, and its role in cure trials. The limitations of broadly neutralizing antibodies are the current need for primary resistance testing, the still unclear number of antibodies that must be combined, the lack of penetration in anatomical reservoirs, and the role they might play in cure studies. We compare the advantages and disadvantages of "classical ART" and therapy based on broadly neutralizing antibodies. We conclude that broadly neutralizing antibodies still need considerable improvements before they can be considered an alternative to classical ART. Competing Interests: Potential conflicts of interest. L. J. W. reports consulting fees, advisory fees, speaker fees, and grant support from ViiV, Janssen, Gilead, MSD, Theratech, Cipla, and Mylan, including support for travel from ViiV (Conference on Retroviruses and Opportunistic Infections travel via British HIV Association). R. d. M.-B. reports personal fees (speaker fee) and nonfinancial support from Janssen, nonfinancial support and personal fees (speaker fee) from ViiV, and nonfinancial support and personal fees (speaker fee) from Gilead, outside the submitted work. S. P. reports speaker fees from Gilead ViiV and MSD and nonfinancial support from Gilead. J. R. A. reports advisory fees, speaker fees, and grant support from ViiV, GSK, Janssen, Gilead, MSD, and Aelix. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu